Abstract
with respect to FCXM because of the high B-cell were added to the cell pellet. The cells were then incubated fluorescence background. The purpose of our study with 100 ml of the recipient serum for 30 min at 37°C. After was to evaluate the influence of a pretransplant positive two washes with normal saline (5 min at 600 g) a further B-cell FCXM (B-FCXM ) on the survival of a renal incubation of 30 min at 4°C was performed with 100 ml of graft.
fluorescein isothiocyanate (FITC )-conjugated F(ab∞) 2 goat antihuman IgG ( Kallestad Diagnostics, Marnes La Coquette), diluted 1/200 in normal saline. The cells were
Subjects and methods
then washed twice, resuspended in 200 ml of normal saline and analysed. Results with current sera were retained for Patients analysis in this study. A pool of sera negative for anti-HLA antibodies from donors of AB blood type was used as We analysed 145 consecutive cadaveric renal transplantations negative control. The positive control consisted of a pool of performed in our institution from May 1991 to September sera from highly sensitized patients (PRA>90%). 1995. All grafts were transplanted after a negative IgG T-CDCXM with both current and historical sera. Flow-cytometry analysis Pretransplant transfusion was not systematicaly performed. Immunosupressive therapy included corticosteroids, azathio-The analysis was performed on a FACScan (Bectonprine, cyclosporine, and anti-thymocyte globulin (ATG Dickinson), using a Lysis software. The data were collected 3mg/kg/day for 10 days after transplantation until June using logarithmic amplification and viable lymphocytes were 1993; after that date, one bolus of 9 mg/kg was added at the gated on forward and side scatter profiles. A gate was then time of the transplantation surgery). Three patients were set on cells bearing PE fluorescence (minimum of 1000 excluded from the analysis due to non-compliance to immu-events). Logarithmic amplification was used to detect the nosupressive therapy. FCXM data of seven other recipients FITC fluorescence, and fluorescence intensity was displayed were not available and were therefore excluded from the on a 1024-channel four-decade log scale. A cut-off value for analysis. Graft loss was recorded on the date of return to positivity was established at 40 channel mean fluorescence dialysis, transplant nephrectomy, or death with a func-shift to T-FCXM and 60 channel shift to B-FCXM. Results tioning graft.
were then expressed as a mean fluorescence index (FI ) (negative control: 0%; positive control: 100% control ), calcu-
Complement-dependent cytotoxicity crossmatch
lated as follows:
Donor lymphocytes were obtained from lymph nodes and/or FI= mean FITC fluorescence of the patient's serum −mean FITC fluorescence of the negative control mean FITC fluorescence of the positive control −mean FITC fluorescence of the negative control spleen after Ficoll-Hypaque centrifugation and evaluated for cell viability by Tripan Blue exclusion. Cells were used to concomitantly perform CDCXM and FCXM with current and historical sera. The CDCXM were performed using a A FI>10% was considered as a positive flow-cytometry fluorescence modified NIH test [13] as follows: 1 ml of a crossmatch. donor cell suspension of unseparated total lymphocytes (at 2×106 cells/ml ) were incubated with 1 ml of recipient serum in Terasaki trays under oil. Following 30 min incubation at Anti-HLA antibodies screening 4°C, 22°C and 37°C, 3 ml of rabbit complement was added and incubated for 60 min at 22°C. Cytotoxicity was then The recipients' sera were tested regularly for the presence of evaluated on fluorescence inverted microscope after addition anti-HLA class I and class II antibodies (panel reactive of 3 ml of acridine orange/ethidium bromide. In parallel, T antibodies, PRA) using the complement-dependent cytotoxand B lymphocytes (separated with immunomagnetic beads, icity technique described above. A recipient's serum was first DynabeadsA) were used as target cells (at 22°C for first tested at his or her registration on the renal transplantation incubation and 30 min for the complement step). Results waiting list. The serum was then tested every 3 months except were obtained by evaluating the proportion of dead cells if a sensitization event occurred (e.g. blood transfusion). In (red fluorescent) among the viable cells (green fluorescent) this case, samples of serum collected before transfusion and on a arbitrary scale of 0 (no dead cells) to 4 (100% of dead after 8, 15, and 21 days were tested. For anti-HLA class I cells). Recipient serum was treated with Dithiothreitol (DTT ) antibodies screening, the sera were tested by incubation with to reduce IgM antibodies (36 ml of serum+4 ml of DTT a panel of 30 cells, selected to represent all frequently 0.1 M incubated for 30 min at 22°C ). DTT treated serum encountered HLA specificities as well as most of the rarer was then used to perform the crossmatch with unseparated ones. If a positive screening was found, the serum was tested lymphocytes as described above. Five minutes before addition on an additional panel of 30 different cells to further identify of complement, 1 ml of 0.02 M cysteine was added to block the HLA specificities of the antibody. For anti-HLA class II complement inactivation by DTT. Positive and negative antibodies screening, the serum was incubated with platelet controls using known polyspecific and negative anti-HLA pools of 50 donors for 1 h at 22°C and at 4°C (twice with antibodies respectively were performed for all crossmatches. two different pools), in order to absorb the anti-HLA class I antibodies eventually present. The serum was then tested over a panel of 36 selected cells, separated in B and T
Flow-cytometry crossmatch
lymphocytes (used as absorption control ). Anti-HLA class I and II antibodies screening was performed with and without FCXM were performed as follows: 106 donor lymphocytes were centrifuged and 3 ml of phycoerythrin (PE)-conjugated DTT reduction of IgM antibodies and only DTT-resistant antibodies were included in the PRA. CD3 (Immunotech, Marseille) or 100 ml of PE-conjugated
Statistical analysis
B-FCXM was greater in patients previously transplanted compared with first transplants recipients (36% Statistical analysis was performed using SigmaStat and vs 14%, P:0.04). Patients with pre-transplant antiSigmaPlot software 1.02 version (Jandel Scientific). HLA class I antibodies (current PRA >10%) had a Mann-Whitney rank sum test and x2-test (with Yates correc-higher incidence of a positive B-FCXM compared with tion factor) were performed when indicated. Recipient and nonsensitized recipients (PRA <10%) (56% vs 10%, graft's cumulated survival were generated by Kaplan-Meyer P<0.001).
analysis and compared by log-rank test at 12 and 48 months post-transplantation (Á10 recipients at risk). A P value <0.05 was considered as statistically significant.
Recipient and graft's survival
Median recipient follow-up was 58.6 months (0.1-83.6 months). Recipient's survival ( Kaplan-Meyer analysis)
Results
in positive and negative B-FCXM groups were similar at 48 months (84% vs 91% respectively, P:ns). In B-FCXM results and correlation with the CDCXM contrast, graft survival at 48 months was poorer in Nineteen recipients were grafted with a positive positive B-FCXM group (57%, 10 recipients at risk) B-FCXM. One hundred and sixteen recipients were than in negative B-FCXM group (79%, 74 patients at grafted with a negative B-FCXM. Mean donor's age risk; P:0.02). Furthermore, earlier graft survival ana-(35.9 and 40.1 years, respectively positive and negative lysis shows that at 12 months post-transplant there B-FCXM; P:ns) as well as mean recipient's age (48.8 was already a significant difference between positive and 45.9 years, respectively positive and negative and negative B-FCXM groups (68% vs 90% respect-B-FCXM; P: ns) were similar in both groups of recipi-ively, P:0.007, Figure 1 ). ents. The degree of HLA mismatching and length of cold-ischaemia time were also similar in both groups Influence of immunological risks factors in the positive ( Table 1 ). The B-CDCXM was positive for five recipi-B-FCXM group ents in the positive B-FCXM group (26%) and for Nine recipients lost their graft in the positive B-FCXM eight patients in the negative B-FCXM group (7%), group, all but one (death with a functioning graft) as P<0.05. All the eight recipients in the negative a consequence of acute and/or chronic rejection. No B-FCXM group with a positive B-CDCXM had a differences were apparent in pretransplant anti-HLA negative post-DTT CDCXM. In contrast, CDCXM class I alloimmunization as well as retransplantation using unseparated lymphocytes (with or without DTT ) frequency between the patients who lost their graft was negative in the five recipients with both a positive and the patients who did not ( Table 2 ), but because B-CDCXM and B-FCXM. Of the 19 recipients grafted of small numbers, no statistical analysis was performed. with a positive B-FCXM, six (31%) also had a positive Among the 19 recipients with a positive B-FCXM, T-FCXM, while only three recipients (2%) grafted graft loss was observed both in recipients with a with a negative B-FCXM had also a positive T-FCXM positive T-FCXM (four out of six) and negative (P<0.001).
T-FCXM (five out of 13, P:ns). Autologous crossmatches (CDCXM ) were performed in 13 recipiInfluence of gender, previous transplants and/or presence ents and were found to be negative. When sera used of anti-HLA class I antibodies for the crossmatch were available (13 recipients), we performed a retrospective screening for anti-HLA class There was a greater number of females in the positive B-FCXM than in the negative B-FCXM (63% vs 32%, II antibodies by the standard CDCXM technique. In the positive sera, no anti-donor specificity could be respectively, P<0.05). The incidence of a positive transplantation, were associated to positive B-FCXM ( Table 1) . This association has been also described in other studies [12, 16 ] . No difference was found in cold found. Two patients out of 10 with no anti-HLA class ischaemic time or degree of HLA mismatch between I antibodies were found to be positive for anti-HLA both groups, suggesting these factors were not involved class II antibodies. No difference was apparent in the in the observed difference in graft survival. proportion of anti-HLA class II alloimmunization
In the positive B-FCXM group, as one could expect between the patients who lost their graft and the from the high sensitivity of FCXM, the five recipients patients who did not ( Table 2 ). In addition, the fluowith a positive B-CDCXM were also found positive rescence index (FI ) of the B-FCXM was equivalent in the two subgroups of patients.
by FCXM. However, B-cell positivity was detected only by FCXM in 14 patients. We also found eight plantation), to consider to transplant with the understanding that there is an increased risk for poor graft recipients with a positive B-CDCXM and negative B-FCXM. However, CDXM in all these recipients was survival. also positive against unseparated lymphocytes as target 
